Claims

1. A composition comprising a fusion protein comprising at least two cytokines,

   wherein the cytokines are human chemokine (C motif) ligand 1 (XCL1) and human interferon alpha 2 (IFNα2), and

   wherein the human IFNα2 comprises a mutation that reduces binding activity to its receptor as compared to wild type cytokine and human XCL1 is a wild-type cytokine which provides cell-specific targeting that restores activity of the mutant cytokine on the targeted cells.

2. The composition of claim 1, further comprising a linker.

3. The composition of claim 2, wherein the linker is one or more GSS repeats.

4. The use of the composition of any one of the above claims in the manufacture of a medicament for stimulating an immune response.

5. The composition of any one of the claims 1-3 for use as a medicament.

6. The composition of any one of the claims 1-3 for use in stimulating an immune response.